Navlimetostat (BMS986504), a clinical stage PRMT5 inhibitor sensitizes MTAP-deleted tumors to IO combination therapy (ESMO Asia 2026) - Oct 1, 2026 - Abstract #676P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Combination therapy • Oncology • MTAP
|
|
Vinay Dubey; Vakkil Mariyappan; Manmita Mazumder; Kiranmayi Vemuri; Miguel Mata; Tejashree Patel; Neelam Kumari; Marsheena Nelleri; Shanawaz Ghouse; Lynda Groocock; Patrick Hagner; Anita Gandhi; Sambuddho Mukherjee
|